Radiopharm Theranostics (RADX) burns $52.8M cash, ends year with $4.1M and lines up A$18.5M equity raise
Rhea-AI Filing Summary
Radiopharm Theranostics Ltd (RADX) reported a sharp deterioration in results for the year ended 30 June 2026. Revenue from contracts with customers fell 23.8% to $2,767,888, while loss attributable to owners increased 50.3% to $55,149,150, driven mainly by substantially higher research and development spending.
The group’s total loss was $56,950,494 and net assets declined to $22,323,683 from $42,871,904. Cash reserves dropped to $4,138,074 (30 June 2025: $29,116,835) after net operating cash outflows of $52,782,838. Net tangible assets per share were a negative 0.45 cents (2025: negative 0.16 cents), reflecting balance sheet strain.
R&D expenses rose to $49,962,899 (2025: $27,515,194), focused on programs including NanoMab, R&D Ventures, Diaprost and Pivalate – Imperial. Ownership in Radiopharm Ventures, LLC increased to 87.5%. Audited financial statements are expected by the end of September 2026 and are anticipated to include a material uncertainty in relation to going concern. On 24 July 2026 the company announced an institutional offer of A$12.5 million and a A$6 million Share Purchase Plan.
Positive
- A$18.5 million in capital raising initiatives announced after year-end (A$12.5 million institutional offer plus A$6 million Share Purchase Plan), which, if completed, would add to liquidity compared with the $4,138,074 cash balance at 30 June 2026.
Negative
- Revenue declined 23.8% to $2,767,888 while loss attributable to owners increased 50.3% to $55,149,150, indicating significantly higher losses on a smaller revenue base.
- Cash reserves fell from $29,116,835 to $4,138,074 with net operating cash outflows of $52,782,838, materially weakening the liquidity position.
- Net tangible assets per ordinary security deteriorated to negative 0.45 cents (2025: negative 0.16 cents), reflecting increased accumulated losses against tangible asset backing.
- The company expects its audited financial statements for the year ended 30 June 2026 to include a material uncertainty in relation to going concern.
Filing Explained
The July 24 financing was still proposed: 448,839,531 new shares in one tranche, while 384,493,800 shares were described as underlying the U.S. offering.
As a Form 6-K, this report furnishes material information published in the company’s home market and includes its preliminary final report and financing update.
The July 24 post-year-end financing was disclosed as proposed: a placement would issue approximately
If the placement shares are issued, the total share count would increase and existing holders’ percentage ownership would be reduced; the filing does not establish that either offering had settled when this report was filed.
The Form 6-K is incorporated by reference into the company’s Form F-3 registration statement, which gives the disclosure registration significance but does not by itself show that the registered securities were sold or that proceeds were received.
Key Figures
Key Terms
Appendix 4E regulatory
material uncertainty in relation to going concern financial
contingent consideration financial
R&D tax incentive financial
non-controlling interest financial
FAQ
How did Radiopharm Theranostics (RADX) perform financially for the year ended 30 June 2026?
What happened to Radiopharm Theranostics (RADX) cash and liquidity in FY 2026?
What going concern disclosure is expected for Radiopharm Theranostics (RADX)?
How much did Radiopharm Theranostics (RADX) spend on research and development in FY 2026?
What post year-end equity raising did Radiopharm Theranostics (RADX) announce?
What is Radiopharm Theranostics (RADX) ownership in Radiopharm Ventures, LLC?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of August 2026
Commission File Number: 001-41621
RADIOPHARM THERANOSTICS LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
RADIOPHARM THERANOSTICS LIMITED
EXPLANATORY NOTE
Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on August 28, 2026 titled:
“Appendix 4E and Preliminary Final Report”
A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.
This Form 6-K, including the exhibits hereto, is incorporated by reference into the registration statement of the Company on Form F-3 (File No. 333-292178) and forms part thereof to the extent not superseded by documents or reports subsequently filed by the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934.
1
EXHIBITS
| Exhibit Number |
Description | |
| 99.1 | Appendix 4E and Preliminary Final Report |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| RADIOPHARM THERANOSTICS LIMITED | ||
| Date: August 28, 2026 | By: | /s/ Amritha Sushil |
| Amritha Sushil | ||
| Company Secretary | ||
3
Exhibit 99.1
| Radiopharm Theranostics Limited Appendix 4E Preliminary final report |
 |
1. Company details
| Name of entity: | Radiopharm Theranostics Limited |
| ABN: | 57 647 877 889 |
| Reporting period: | For the year ended 30 June 2026 |
| Previous period: | For the year ended 30 June 2025 |
2. Results for announcement to the market
| $ | ||||||||
| Revenue from contracts with customers | down | 23.8% to | 2,767,888 | |||||
| Loss from ordinary activities after tax attributable to the owners of Radiopharm Theranostics Limited | up | 50.3% to | (55,149,150 | ) | ||||
| Loss for the year attributable to the owners of Radiopharm Theranostics Limited | up | 50.3% to | (55,149,150 | ) | ||||
No dividends have been paid or declared by the group for the current financial year. No dividends were paid for the previous financial year.
3. Explanation of results
The group reported a loss for the year ended 30 June 2026 of $56,950,494 (30 June 2025: $38,342,457). The increase in loss in the current year compared to prior year is mainly attributable to higher research and development expenditures incurred during the year to advance and broaden the developmental phases of ongoing clinical studies.
The group's net assets for the year ended 30 June 2026 decreased to $22,323,683 (30 June 2025: $42,871,904). Net assets decreased primarily due to a decrease in cash balances attributable to higher investment in research and development activities during the financial year. As at 30 June 2026, the group had cash reserves of $4,138,074 (30 June 2025: $29,116,835).
The Appendix 4E financial report follows, with the further details to be included in the audited financial statements is expected to be released by 30 September 2026.
4. Net tangible assets per security
| 30 June 2026 Cents | 30 June 2025 Cents | |||||||
| Net tangible assets per ordinary security | (0.45 | ) | (0.16 | ) | ||||
5. Changes in controlled entities
During the year ended 30 June 2026, Radiopharm Theranostics increased its ownership in Radiopharm Ventures, LLC, a joint venture created with The University of Texas M.D. Anderson Cancer Center (MDACC) from 75% to 87.5%.
There have been no other changes in controlled entities during the year ended 30 June 2026.
| Radiopharm Theranostics Limited Appendix 4E Preliminary final report |
|
6. Other information required by Listing Rule 4.3A
| a. | Details of individual and total dividends or distributions and dividend or distribution payments: N/A |
| b. | Details of any dividend or distribution reinvestment plans: N/A |
| c. | Details of associates and joint venture entities: |
| Ownership interest held by the group | ||||||||||
| Name of entity | Place of business / country of incorporation | 2026 | 2025 | |||||||
| % | % | |||||||||
| Radiopharm Ventures LLC | United States | 87.5 | 75 | |||||||
On 9 July 2022, Radiopharm Theranostics (USA) Inc. and The University of Texas MD Anderson Cancer Center formed Radiopharm Ventures, LLC, a joint venture to develop novel radiopharmaceutical therapeutic products for cancer. The joint venture continues to focus on developing products based on MD Anderson intellectual property. On 26 August 2024, Radiopharm announced they had increased their ownership in Radiopharm Ventures from 51% to 75%. During the year ended 30 June 2026, Radiopharm Theranostics increased its ownership in Radiopharm Ventures, LLC, from 75% to 87.5%.
d. Other information: N/A
7. Audit
The financial statements are currently in the process of being audited. Audited financial statements along with the independent auditor report for the year ended 30 June 2026 is expected to be released by the end of September 2026 with a material uncertainty in relation to going concern.
Radiopharm Theranostics Limited
ABN 57 647 877 889
Preliminary Final Report - 30 June 2026
| Radiopharm Theranostics Limited Contents 30 June 2026 |
|
| Statement of profit or loss and other comprehensive income | 2 | |
| Statement of financial position | 3 | |
| Statement of changes in equity | 4 | |
| Statement of cash flows | 6 | |
| Notes to the financial statements | 7 |
General information
The financial statements cover Radiopharm Theranostics Limited as a consolidated entity consisting of Radiopharm Theranostics Limited and the entities it controlled at the end of, or during, the year. The financial statements are presented in Australian dollars, which is Radiopharm Theranostics Limited's functional and presentation currency.
Radiopharm Theranostics Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:
Level 3, 62 Lygon Street, Carlton VIC 3053
1
| Radiopharm Theranostics Limited Statement of profit or loss and other comprehensive income For the year ended 30 June 2026 |
|
| Consolidated | ||||||||||
| 30 June | 30 June | |||||||||
| Note | 2026 | 2025 | ||||||||
| $ | $ | |||||||||
| Revenue | ||||||||||
| Revenue from contracts with customers | 2 | 2,767,888 | 3,633,422 | |||||||
| Cost of sales | (2,504,499 | ) | (3,594,146 | ) | ||||||
| Gross profit | 263,389 | 39,276 | ||||||||
| Other income and expense items | 10,734,382 | 10,256,740 | ||||||||
| Other losses | (868,162 | ) | (351,646 | ) | ||||||
| Expenses | ||||||||||
| General and administrative expenses | 3 | (16,215,702 | ) | (14,638,013 | ) | |||||
| Research and development expenses | 4 | (49,962,899 | ) | (27,515,194 | ) | |||||
| Share-based payments expenses | (2,405,955 | ) | (1,895,348 | ) | ||||||
| Movement in contingent consideration | 1,671,289 | (4,069,680 | ) | |||||||
| Operating loss | (56,783,658 | ) | (38,173,865 | ) | ||||||
| Finance expenses | (112,396 | ) | (65,300 | ) | ||||||
| Loss before income tax expense | (56,896,054 | ) | (38,239,165 | ) | ||||||
| Income tax expense | (54,440 | ) | (103,292 | ) | ||||||
| Loss after income tax expense for the year | (56,950,494 | ) | (38,342,457 | ) | ||||||
| Other comprehensive income | ||||||||||
| Items that may be reclassified subsequently to profit or loss | ||||||||||
| Exchange differences on translation of foreign operations | 621,440 | 464,034 | ||||||||
| Other comprehensive income for the year, net of tax | 621,440 | 464,034 | ||||||||
| Total comprehensive loss for the year | (56,329,054 | ) | (37,878,423 | ) | ||||||
| Loss for the year is attributable to: | ||||||||||
| Non-controlling interest | (1,801,344 | ) | (1,639,368 | ) | ||||||
| Owners of Radiopharm Theranostics Limited | (55,149,150 | ) | (36,703,089 | ) | ||||||
| (56,950,494 | ) | (38,342,457 | ) | |||||||
| Total comprehensive loss for the year is attributable to: | ||||||||||
| Non-controlling interest | (1,801,344 | ) | (1,639,368 | ) | ||||||
| Owners of Radiopharm Theranostics Limited | (54,527,710 | ) | (36,239,055 | ) | ||||||
| (56,329,054 | ) | (37,878,423 | ) | |||||||
| Cents | Cents | |||||||
| Loss per share for loss attributable to the ordinary equity holders of the group: | ||||||||
| Basic and diluted loss per share | (1.79 | ) | (1.76 | ) | ||||
The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes
2
| Radiopharm Theranostics Limited Statement of financial position As at 30 June 2026 |
|
| Consolidated | ||||||||||
| 30 June | 30 June | |||||||||
| Note | 2026 | 2025 | ||||||||
| $ | $ | |||||||||
| Assets | ||||||||||
| Current assets | ||||||||||
| Cash and cash equivalents | 5 | 4,138,074 | 29,116,835 | |||||||
| Trade and other receivables | 6 | 17,447,428 | 10,400,060 | |||||||
| Other current assets | 340,194 | 337,093 | ||||||||
| Total current assets | 21,925,696 | 39,853,988 | ||||||||
| Non-current assets | ||||||||||
| Property, plant and equipment | 46,136 | 53,466 | ||||||||
| Intangible assets | 38,161,747 | 46,574,422 | ||||||||
| Total non-current assets | 38,207,883 | 46,627,888 | ||||||||
| Total assets | 60,133,579 | 86,481,876 | ||||||||
| Liabilities | ||||||||||
| Current liabilities | ||||||||||
| Trade and other payables | 7 | 10,531,800 | 9,340,993 | |||||||
| Other financial liabilities | 8 | 6,860,850 | 3,421,337 | |||||||
| Employee benefits | 697,907 | 450,104 | ||||||||
| Deferred revenue | 806,410 | 1,720,551 | ||||||||
| Total current liabilities | 18,896,967 | 14,932,985 | ||||||||
| Non-current liabilities | ||||||||||
| Other financial liabilities | 8 | 18,912,929 | 28,676,987 | |||||||
| Total non-current liabilities | 18,912,929 | 28,676,987 | ||||||||
| Total liabilities | 37,809,896 | 43,609,972 | ||||||||
| Net assets | 22,323,683 | 42,871,904 | ||||||||
| Equity | ||||||||||
| Share capital | 9 | 209,933,371 | 176,558,493 | |||||||
| Other equity | - | 849,544 | ||||||||
| Other reserves | 14,414,155 | 13,116,919 | ||||||||
| Accumulated losses | (199,660,317 | ) | (145,732,952 | ) | ||||||
| Non-controlling interest | (2,363,526 | ) | (1,920,100 | ) | ||||||
| Total equity | 22,323,683 | 42,871,904 | ||||||||
The above statement of financial position should be read in conjunction with the accompanying notes
3
| Radiopharm Theranostics Limited Statement of changes in equity For the year ended 30 June 2026 |
|
| Attributable to owners of Radiopharm Theranostics Limited | ||||||||||||||||||||||||
| Consolidated | Share | Other | Other reserves | Accumulated | Non-controlling | Total | ||||||||||||||||||
| $ | $ | $ | $ | $ | $ | |||||||||||||||||||
| Balance at 1 July 2024 | 100,681,716 | 849,544 | 37,930,072 | (111,338,770 | ) | (769,276 | ) | 27,353,286 | ||||||||||||||||
| Loss after income tax expense for the year | - | - | - | (36,703,089 | ) | (1,639,368 | ) | (38,342,457 | ) | |||||||||||||||
| Other comprehensive income for the year, net of tax | - | - | 464,034 | - | - | 464,034 | ||||||||||||||||||
| Total comprehensive income for the year | - | - | 464,034 | (36,703,089 | ) | (1,639,368 | ) | (37,878,423 | ) | |||||||||||||||
| Transactions with owners in their capacity as owners: Contributions of equity, net of transaction costs(note 9) | 74,915,537 | - | (23,885,229 | ) | - | - | 51,030,308 | |||||||||||||||||
| Issue of options | - | - | 2,157,778 | - | - | 2,157,778 | ||||||||||||||||||
| Issue of shares for milestone completion | 741,400 | - | - | - | - | 741,400 | ||||||||||||||||||
| Equity-settled payments | 219,840 | - | (231,115 | ) | - | - | (11,275 | ) | ||||||||||||||||
| Expiration of options | - | - | (2,797,451 | ) | 2,797,451 | - | - | |||||||||||||||||
| Forfeiture of options | - | - | (221,170 | ) | - | - | (221,170 | ) | ||||||||||||||||
| Cancellation of shares to be issued | - | - | (300,000 | ) | - | - | (300,000 | ) | ||||||||||||||||
| Increase in ownership in RAD Ventures | - | - | - | (488,544 | ) | 488,544 | - | |||||||||||||||||
| - | - | - | - | - | - | |||||||||||||||||||
Balance at 30 June 2025 | 176,558,493 | 849,544 | 13,116,919 | (145,732,952 | ) | (1,920,100 | ) | 42,871,904 | ||||||||||||||||
The above statement of changes in equity should be read in conjunction with the accompanying notes
4
| Radiopharm Theranostics Limited Statement of changes in equity For the year ended 30 June 2026 |
|
| Attributable to owners of Radiopharm Theranostics Limited | ||||||||||||||||||||||||
| Consolidated | Share | Other | Other reserves | Accumulated | Non-controlling | Total | ||||||||||||||||||
| $ | $ | $ | $ | $ | $ | |||||||||||||||||||
| Balance at 1 July 2025 | 176,558,493 | 849,544 | 13,116,919 | (145,732,952 | ) | (1,920,100 | ) | 42,871,904 | ||||||||||||||||
| Loss after income tax expense for the year | - | - | - | (55,149,150 | ) | (1,801,344 | ) | (56,950,494 | ) | |||||||||||||||
| Other comprehensive income for the year, net of tax | - | - | 621,440 | - | - | 621,440 | ||||||||||||||||||
| Total comprehensive income for the year | - | - | 621,440 | (55,149,150 | ) | (1,801,344 | ) | (56,329,054 | ) | |||||||||||||||
| Transactions with owners in their capacity as owners: Contributions of equity, net of transaction costs (note 9) | 33,374,878 | - | - | - | - | 33,374,878 | ||||||||||||||||||
| Issue of options | - | - | 2,740,119 | - | - | 2,740,119 | ||||||||||||||||||
| Expiration of options | - | - | (1,730,159 | ) | 1,730,159 | - | - | |||||||||||||||||
| Forfeiture of options | - | - | (334,164 | ) | - | - | (334,164 | ) | ||||||||||||||||
| Increase in ownership in RAD Ventures | - | - | - | (1,357,918 | ) | 1,357,918 | - | |||||||||||||||||
| Derecognition of Pharma15 | - | (849,544 | ) | - | 849,544 | - | - | |||||||||||||||||
| Balance at 30 June 2026 | 209,933,371 | - | 14,414,155 | (199,660,317 | ) | (2,363,526 | ) | 22,323,683 | ||||||||||||||||
The above statement of changes in equity should be read in conjunction with the accompanying notes
5
| Radiopharm Theranostics Limited Statement of cash flows For the year ended 30 June 2026 |
|
| Consolidated | ||||||||||
| Note | 30
June | 30
June | ||||||||
| $ | $ | |||||||||
| Cash flows from operating activities | ||||||||||
| Receipts from customers (inclusive of GST) | 536,384 | 5,353,973 | ||||||||
| Payments to suppliers and employees (inclusive of GST) | (58,353,869 | ) | (42,799,759 | ) | ||||||
| Interest received | 549,213 | 800,309 | ||||||||
| Research and development tax incentive received | 4,485,434 | - | ||||||||
| Net cash used in operating activities | (52,782,838 | ) | (36,645,477 | ) | ||||||
| Cash flows from investing activities | ||||||||||
| Receipts for sale of intellectual property | - | 2,997,592 | ||||||||
| Payments of license fee liabilities | (5,420,869 | ) | (1,226,994 | ) | ||||||
| Net cash from/(used in) investing activities | (5,420,869 | ) | 1,770,598 | |||||||
| Cash flows from financing activities | ||||||||||
| Proceeds from issue of shares | 9 | 35,378,000 | 53,977,902 | |||||||
| Share issue transaction costs | (2,003,122 | ) | (4,738,000 | ) | ||||||
| Repayment of borrowings | - | (1,900,000 | ) | |||||||
| Transaction costs related to loans and borrowings | - | (218,633 | ) | |||||||
| Settlement with Lind | - | (1,689,721 | ) | |||||||
| Net cash from financing activities | 33,374,878 | 45,431,548 | ||||||||
| Net (decrease)/increase in cash and cash equivalents | (24,828,829 | ) | 10,556,669 | |||||||
| Cash and cash equivalents at the beginning of the financial year | 29,116,835 | 18,575,040 | ||||||||
| Effects of exchange rate changes on cash and cash equivalents | (149,932 | ) | (14,874 | ) | ||||||
| Cash and cash equivalents at the end of the financial year | 5 | 4,138,074 | 29,116,835 | |||||||
The above statement of cash flows should be read in conjunction with the accompanying notes
6
| Radiopharm Theranostics Limited Notes to the financial statements 30 June 2026 |
|
Note 1. Segment information
Management has determined based on the reports reviewed by the Chief Operating Decision Maker (CODM) that are used to make strategic decisions, that the group has one reportable segment being the research, development and commercialisation of health technologies. As such, the financial information presented in the body of the financial report represents the results of the Group's sole operating segment. The CODM continues to monitor and review the appropriateness of this segment determination on a regular basis.
Note 2. Revenue from contract with customers
| 30 June | 30 June | |||||||
| 2026 | 2025 | |||||||
| $ | $ | |||||||
| Revenue from contract with customers | ||||||||
| Revenue recognised over time | 2,767,888 | 3,633,422 | ||||||
| Total revenue from continuing operations | 2,767,888 | 3,633,422 | ||||||
During the period ended 30 June 2025, the group entered into a strategic development services contract with Lantheus to advance clinical development of innovative radiopharmaceuticals in Australia.
Note 3. General and administrative expenses
| 30 June | 30 June | |||||||
| 2026 | 2025 | |||||||
| $ | $ | |||||||
| Accounting and audit | 949,683 | 957,895 | ||||||
| Consulting | 406,564 | 286,138 | ||||||
| Depreciation | 7,331 | 7,331 | ||||||
| Employee benefits | 11,186,055 | 10,120,149 | ||||||
| Insurance | 341,658 | 105,762 | ||||||
| Investor relations | 472,262 | 313,671 | ||||||
| Legal | 631,909 | 656,036 | ||||||
| Listing and share registry | 188,341 | 190,795 | ||||||
| Patent costs | 244,529 | 205,017 | ||||||
| Travel and entertainment | 864,801 | 808,546 | ||||||
| Other | 922,569 | 986,673 | ||||||
| 16,215,702 | 14,638,013 | |||||||
7
| Radiopharm Theranostics Limited Notes to the financial statements 30 June 2026 |
|
Note 4. Research and development expenses
| 30 June | 30 June | |||||||
| 2026 | 2025 | |||||||
| $ | $ | |||||||
| Amortisation | 2,698,702 | 2,588,306 | ||||||
| AVb6 Integrin (TRIMT) | 918,221 | 1,876,983 | ||||||
| Consulting Fees R&D | 1,324,355 | 930,292 | ||||||
| hu PSA Anti-body (Diaprost) | 7,011,056 | 2,925,445 | ||||||
| Impairment losses | 5,266,823 | - | ||||||
| R&D Ventures | 11,040,742 | 5,989,964 | ||||||
| NanoMab | 15,070,282 | 7,185,000 | ||||||
| Neoindicate | 351,529 | 437,400 | ||||||
| Pivalate - Imperial | 6,153,044 | 5,184,136 | ||||||
| UCLA | - | 226,063 | ||||||
| Other | 128,145 | 171,605 | ||||||
| 49,962,899 | 27,515,194 | |||||||
The categories shown here align with the intellectual property held by the group and represents the amount of R&D expended on developing the respective intellectual property.
Note 5. Cash and cash equivalents
| Consolidated | ||||||||
| 30 June | 30 June | |||||||
| 2026 | 2025 | |||||||
| $ | $ | |||||||
| Current assets | ||||||||
| Cash at bank | 4,138,074 | 29,116,835 | ||||||
| 4,138,074 | 29,116,835 | |||||||
(i) Reconciliation to cash flow statement
The above figures reconcile to the amount of cash shown in the consolidated statement of cash flows at the end of the financial year and period, respectively, as follows:
| 30 June | 30 June | |||||||
| 2026 | 2025 | |||||||
| $ | $ | |||||||
| Balance as above | 4,138,074 | 29,116,835 | ||||||
| Balance per statement of cash flows | 4,138,074 | 29,116,835 | ||||||
(ii) Classification as cash equivalents
Term deposits are presented as cash equivalents if they have a maturity of three months or less from the date of acquisition and are repayable with 24 hours notice with no loss of interest.
(iii) Risk exposure
The maximum exposure to credit risk at the end of the reporting year is the carrying amount of each class of cash and cash equivalents mentioned above.
8
| Radiopharm Theranostics Limited Notes to the financial statements 30 June 2026 |
|
Note 6. Trade and other receivables
| 30 June | 30 June | |||||||||||||||||||||||
| 2026 | 2025 | |||||||||||||||||||||||
| Current | Non-current | Total | Current | Non-current | Total | |||||||||||||||||||
| $ | $ | $ | $ | $ | $ | |||||||||||||||||||
| Trade receivables | 1,227,040 | - | 1,227,040 | - | - | - | ||||||||||||||||||
| Accrued receivables(i) | 15,877,895 | - | 15,877,895 | 10,171,532 | - | 10,171,532 | ||||||||||||||||||
| GST and other receivables | 342,493 | - | 342,493 | 228,528 | - | 228,528 | ||||||||||||||||||
| 17,447,428 | - | 17,447,428 | 10,400,060 | - | 10,400,060 | |||||||||||||||||||
(i) Accrued receivables
Accrued receivables comprise $15,877,895 from the Australian Taxation Office in relation to the R&D tax incentive (30 June 2025: $10,171,532). Subsequent to year-end, Radiopharm received $5,780,657 relating to the accrued income recognised at 30 June 2025. This receipt represents the settlement of the outstanding balance and has been recorded as cash in the following financial year.
Note 7. Trade and other payables
| 30 June 2026 | 30 June 2025 | |||||||||||||||||||||||
| Current | Non-current | Total | Current | Non-current | Total | |||||||||||||||||||
| $ | $ | $ | $ | $ | $ | |||||||||||||||||||
| Trade payables | 5,466,476 | - | 5,466,476 | 6,347,397 | - | 6,347,397 | ||||||||||||||||||
| Accrued expenses | 4,836,856 | - | 4,836,856 | 2,750,662 | - | 2,750,662 | ||||||||||||||||||
| Other payables | 228,468 | - | 228,468 | 242,934 | - | 242,934 | ||||||||||||||||||
| 10,531,800 | - | 10,531,800 | 9,340,993 | - | 9,340,993 | |||||||||||||||||||
Note 8. Other financial liabilities
| 30 June 2026 | 30 June 2025 | |||||||||||||||||||||||
| Current | Non-current | Total | Current | Non-current | Total | |||||||||||||||||||
| $ | $ | $ | $ | $ | $ | |||||||||||||||||||
| Diaprost contingent consideration | 1,979,902 | 6,916,482 | 8,896,384 | 1,328,087 | 8,841,829 | 10,169,916 | ||||||||||||||||||
| NanoMab contingent consideration* | 4,502,764 | 1,050,443 | 5,553,207 | 1,832,833 | 4,899,858 | 6,732,691 | ||||||||||||||||||
| NeoIndicate contingent consideration | - | - | - | - | 1,870,454 | 1,870,454 | ||||||||||||||||||
| Pivalate contingent consideration | 378,184 | 1,646,950 | 2,025,134 | 225,245 | 1,933,981 | 2,159,226 | ||||||||||||||||||
| Pharma15 contingent consideration | - | - | - | - | 1,134,164 | 1,134,164 | ||||||||||||||||||
| TRIMT contingent consideration | - | 7,758,256 | 7,758,256 | - | 8,423,667 | 8,423,667 | ||||||||||||||||||
| MD Anderson contingent consideration | - | 1,540,798 | 1,540,798 | 35,172 | 1,573,034 | 1,608,206 | ||||||||||||||||||
| 6,860,850 | 18,912,929 | 25,773,779 | 3,421,337 | 28,676,987 | 32,098,324 | |||||||||||||||||||
| * | Payment to be made in the form of ordinary shares in the company, based on the price of the 7 day volume weighted average price (VWAP) prior to the announcement of the milestone on the ASX. |
9
| Radiopharm Theranostics Limited Notes to the financial statements 30 June 2026 |
|
Note 9. Share capital
| 30 June | 30 June | 30 June | 30 June | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Shares | Shares | $ | $ | |||||||||||||
| Ordinary Shares | ||||||||||||||||
| Ordinary Shares Fully paid | 3,544,216,160 | 2,364,949,502 | 209,933,371 | 176,558,493 | ||||||||||||
(i) Movements in ordinary shares:
| Number of | Total | |||||||
| Details | Shares | $ | ||||||
| Balance at 1 July 2024 | 460,367,051 | 100,681,716 | ||||||
| Issue of ordinary shares at $0.040 pursuant to issue of securities (2024-07-01) | 597,130,727 | 23,885,229 | ||||||
| Issue of ordinary shares at $0.040 pursuant to Tranche 2 placement shares (2024-08-21) | 858,056,603 | 34,322,264 | ||||||
| Issue of ordinary shares at $0.040 pursuant to Tranche 2 placement shares (2024-08-21) | 14,031,195 | 561,248 | ||||||
| Issue of ordinary shares at $0.050 pursuant to Lantheus investment (2024-08-23) | 149,625,180 | 7,481,259 | ||||||
| Issue of ordinary shares at $0.040 pursuant to issue of placement shares (2024-09-13) | 93,750,000 | 3,750,000 | ||||||
| Issue of ordinary shares at $0.036 for the achievement of a milestone (2024-12-13) | 20,594,438 | 741,400 | ||||||
| Issue of ordinary shares at $0.036 pursuant to forfeiture shares (2024-12-16) | 7,091,615 | 219,840 | ||||||
| Issue of ordinary shares at $0.060 pursuant to issue of placement shares to Lantheus (2025-01-20) | 133,333,333 | 8,000,000 | ||||||
| Issue of ordinary shares at $0.025 for the achievement of a milestone (2025-06-12) | 30,969,360 | 774,234 | ||||||
| Less: Transaction costs arising on share issues | - | (3,858,697 | ) | |||||
| Balance at 30 June 2025 | 2,364,949,502 | 176,558,493 | ||||||
| Balance at 1 July 2025 | 2,364,949,502 | 176,558,493 | ||||||
| Issue of ordinary shares at $0.030 pursuant to issue of securities (2025-10-24) | 415,706,190 | 12,471,186 | ||||||
| Issue of ordinary shares at $0.030 pursuant to issue of securities (2025-12-05) | 12,599,991 | 378,000 | ||||||
| Issue of ordinary shares at $0.030 pursuant to issue of securities (2025-12-09) | 750,960,477 | 22,528,814 | ||||||
| Less: Transaction costs arising on share issues | - | (2,003,122 | ) | |||||
| Balance at 30 June 2026 | 3,544,216,160 | 209,933,371 | ||||||
Note 10. Events after the reporting period
On July 24, 2026, the Company announced an A$12.5 million institutional offer and launched A$6 million Share Purchase Plan. The institutional offer comprises of two-tranche placement of approximately 448,839,531 new fully paid ordinary shares at A$0.015 per New Share to an Australian international institutional and sophisticated investors; and 384,493,800 underlying ordinary shares at US$3.16 per ADS to a US Direct Registration Offering. The Share Purchase Plan offer closes on 10 September 2026.
No other matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.
10
